Cargando…

Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia

Our goal was to examine the associations of the 388A>G and 521T>C polymorphisms in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene with hepatic function, baseline lipid levels, and the lipid-lowering efficiency of simvastatin. We recruited 542 patients with hyperlipidemia. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Xiangyu, Gong, Chen, Weinstock, Justin, Cheng, Jun, Hu, Shengnan, Venners, Scott A., Hsu, Yi-Hsiang, Wu, Suwen, Zha, Xiangdong, Jiang, Shanqun, Li, Yong, Pan, Faming, Xu, Xiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714829/ https://www.ncbi.nlm.nih.gov/pubmed/30336686 http://dx.doi.org/10.1177/1076029618805863

Ejemplares similares

Effect modification by region in the associations of LEP G2548A and LEPR Q223R polymorphisms with statin-induced CK elevation
por: Jiang, Shanqun, et al.
Publicado: (2017)

Effects of SLCO1B1 Genetic Variant on Metabolite Profile in Participants on Simvastatin Treatment
por: Fernandes Silva, Lilian, et al.
Publicado: (2022)

Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T > C Polymorphism
por: Zeng, Weiwei, et al.
Publicado: (2022)

Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in Patients With Hyperlipidemia
por: Chen, Yu-An, et al.
Publicado: (2018)

Effect of lipid lowering tablet on blood lipid in hyperlipidemia model rats
por: Kong, Xuejun, et al.
Publicado: (2018)

SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria
por: Sortica, Vinicius A, et al.
Publicado: (2017)

Candidate‐Gene Study of Functional Polymorphisms in SLCO1B1 and CYP3A4/5 and the Cholesterol‐Lowering Response to Simvastatin
por: Kitzmiller, JP, et al.
Publicado: (2016)

Comparing Simvastatin Monotherapy V/S Simvastatin-Ezetimibe Combination Therapy for the Treatment of Hyperlipidemia: A Meta-Analysis and Review
por: Chauhan, Dhruva, et al.
Publicado: (2022)

The effect of adropin on lipid and glucose metabolism in rats with hyperlipidemia
por: Akcılar, Raziye, et al.
Publicado: (2016)

Hyperlipidemia: A Review of the Novel Methods for the Management of Lipids
por: Ezeh, Kosisochukwu J, et al.
Publicado: (2021)

Simvastatin-Loaded Lipid Emulsion Nanoparticles: Characterizations and Applications
por: Ullah, Faiz, et al.
Publicado: (2022)

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins
por: Dou, Ye, et al.
Publicado: (2015)

Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia
por: Gaggini, Melania, et al.
Publicado: (2022)

Effects of the duration of hyperlipidemia on cerebral lipids, vessels and neurons in rats
por: Yang, Weichun, et al.
Publicado: (2017)

Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021)

The efficacy and safety of Simvastatin in the treatment of lipid abnormalities in diabetes mellitus
por: Okeoghene, Ogbera A., et al.
Publicado: (2013)

Hyperlipidemia and lipid-lowering therapy in diabetic retinopathy (DR): A bibliometric study and visualization analysis in 1993–2023
por: Tan, Haishan, et al.
Publicado: (2023)

Association between single nucleotide polymorphism SLCO1B1 gene and simvastatin pleiotropic effects measured through flow-mediated dilation endothelial function parameters
por: Andrianto,, et al.
Publicado: (2022)

Transcriptome analysis of healthy and fatty liver revealed that inhibition of SLCO1B3 induces abnormal liver metabolism and lipid synthesis
por: Zhu, Xiaomu, et al.
Publicado: (2023)

Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin
por: Al-Asmari, Abdulrahman K, et al.
Publicado: (2017)

A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
por: Lehtisalo, Minna, et al.
Publicado: (2022)

The effect of genistein on lipid levels and LDLR, LXRα and ABCG1 expression in postmenopausal women with hyperlipidemia
por: Zhang, Tao, et al.
Publicado: (2019)

SLCO1B1 Polymorphisms and Statin-Induced Myopathy
por: Stewart, Alison
Publicado: (2013)

Effects of Simvastatin on Lipid Metabolism in Wild-Type Mice and Mice with Muscle PGC-1α Overexpression
por: Panajatovic, Miljenko V., et al.
Publicado: (2021)

Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model
por: Taylor, Zachary L., et al.
Publicado: (2021)

Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia
por: Sivkov, Andrey, et al.
Publicado: (2021)

Novel SLCO2A1 mutations cause gender-differentiated pachydermoperiostosis
por: Yuan, Lijuan, et al.
Publicado: (2018)

Vitamin D concentrations in familial combined hyperlipidemia: effects of lipid lowering treatment
por: Miñambres, Inka, et al.
Publicado: (2014)

Regulation effect of Aspirin Eugenol Ester on blood lipids in Wistar rats with hyperlipidemia
por: Karam, Isam, et al.
Publicado: (2015)

Interaction of hyperlipidemia and reactive oxygen species: Insights from the lipid-raft platform
por: Amiya, Eisuke
Publicado: (2016)

Palmiwon attenuates hepatic lipid accumulation and hyperlipidemia in a menopausal rat model
por: Go, Hiroe, et al.
Publicado: (2015)

Comparison of Erythrocyte Membrane Lipid Profiles between NAFLD Patients with or without Hyperlipidemia
por: Chen, Wenbin, et al.
Publicado: (2020)

Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia
por: Hu, Bo, et al.
Publicado: (2022)

Distribution of lipid levels and prevalence of hyperlipidemia: data from the NHANES 2007–2018
por: Li, Zhenhan, et al.
Publicado: (2022)

Ascophyllum nodosum and Fucus vesiculosus Extracts Improved Lipid Metabolism and Inflammation in High-Energy Diet–Induced Hyperlipidemia Rats
por: Tung, Yu-Tang, et al.
Publicado: (2022)

LncRNA SLCO4A1-AS1 modulates colon cancer stem cell properties by binding to miR-150-3p and positively regulating SLCO4A1
por: Wu, Kun, et al.
Publicado: (2021)

Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial
por: Reyes-Soffer, Gissette, et al.
Publicado: (2013)

Simvastatin Solid Lipid Nanoparticles for Oral Delivery: Formulation Development and In vivo Evaluation
por: Padhye, S. G., et al.
Publicado: (2013)

Polymorphic variants of SLCO1B1 in neonatal hyperbilirubinemia in China
por: Liu, Jiebo, et al.
Publicado: (2013)

Chronic Enteropathy Associated with SLCO2A1 with Pachydermoperiostosis
por: Tsuzuki, Yoshikazu, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cgvi4gtplao07njjgoc8sslk9d